Micrograph News and Research

RSS

COVID-19 mRNA vaccine or booster during pregnancy benefits mother and baby, study finds

Receiving a COVID-19 mRNA vaccine or booster during pregnancy can benefit pregnant people and their newborn infants, according to findings recently published in Vaccine.

11 Aug 2023

Using bacteriophages to treat bladder infections

About one in two women are affected by cystitis during her lifetime, and many suffer from recurrent urinary tract infections.

21 Jul 2023

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

5 Jul 2023

New method may help identify the essential ingredients for making an effective HIV vaccine

Since it was identified in 1984 as the cause of Acquired Immune Deficiency Syndrome (AIDS), the human immunodeficiency virus (HIV) has infected more than 80 million people and been responsible for some 40 million deaths worldwide, according to the World Health Organization (WHO).

30 May 2023

Rising tide of chronic disease can be traced to impaired salugenesis, incomplete healing

In medicine and science, the term "pathogenesis" describes the origin and development of disease. There is not, however, a broadly accepted term to describe the other half of the equation: the process of healing and recovery.

10 May 2023

NIH researchers gain new insights on rare immune deficiency

In an 11-year study, researchers at the National Institutes of Health have further characterized idiopathic CD4 lymphocytopenia (ICL), a rare immune deficiency that leaves people vulnerable to infectious diseases, autoimmune diseases and cancers.

4 May 2023

Study reveals the mechanism behind oligomeric assembly of a BAR-domain-containing protein

Cell membranes play a critical role by serving as containment units and separating the inner cellular space from the extracellular environment.

26 Apr 2023

UCSD engineers develop a biodegradable polymer system to treat rheumatoid arthritis

A team led by engineers at the University of California San Diego has developed a biodegradable polymer system to treat rheumatoid arthritis, an autoimmune and inflammatory disease, by working in concert with the power of the human immune system.

4 Apr 2023

Study reveals why COVID-19 subvariants spread rapidly among previously infected people

The COVID-19 pandemic has killed nearly 7 million people worldwide (1.1 million in the United States) and severely harmed many millions more, though vaccines and antiviral treatments measurably reduced the potential loss of life and health.

22 Mar 2023

SARS-CoV-2 infection damages the CD8+ T cell response to vaccination

The magnitude and quality of a key immune cell's response to vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, a study has found.

20 Mar 2023

Study suggests a new way to develop intra-tumor immunotherapies to fight head and neck cancer

Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health have identified a strong association between the product of a gene expressed in most cancers, including the most common type of head and neck cancer, and elevated levels of white blood cells that produce antibodies within tumors.

13 Mar 2023

Clinical trial shows safety and immunogenicity of temperature-stable experimental TB vaccine

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.

6 Mar 2023

NIH initiates a clinical trial evaluating an investigational antiviral for treatment of COVID-19

The National Institutes of Health has initiated a multi-site clinical trial evaluating an investigational antiviral for the treatment of COVID-19.

15 Feb 2023

New mouse model demonstrates clear differences in virulence among mpox virus clades

Scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health have removed a major roadblock to better understanding of mpox (formerly, monkeypox).

14 Feb 2023

Experimental vaccine completely protects cynomolgus macaques against lethal Sudan virus

A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.

3 Feb 2023

Experimental vaccine against Marburg virus shows promise in first-in-human clinical trial

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

30 Jan 2023

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined.

18 Jan 2023

Randomized trials demonstrate the safety of Ebola vaccine regimens in adults and children

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to results published today in the New England Journal of Medicine.

15 Dec 2022

NIAID awards more than $12 million for the development of antiviral therapies

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

21 Nov 2022

Study illuminates how a typical gut bacterium spreads through the body

A typical gut bacterium that can spread through the body and cause a serious infection resists natural immune defenses and antibiotics by enhancing its protective outer layer, known as the cell envelope, according to a new study by Weill Cornell Medicine investigators.

10 Nov 2022